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Abstract
Introduction: Obesity is a disease that brings several complications and increases the risk of other diseases like metabolic syndrome,
diabetes mellitus type 2, or coronary heart disease. Disturbances in secretion of adipokines caused by obesity have an influence on the
development of metabolic complications.
The aim of this study was an investigation of adipokines profile in overweight or obese people with metabolic syndrome in comparison to
overweight/obese patients without metabolic syndrome.
Material and methods: The studied groups consisted of 38 obese or overweight patients without metabolic syndrome (nonMS) and
17 with recognized metabolic syndrome (MS), according to International Diabetes Federation (IDF) criteria. All individuals underwent
anthropometrical and blood-pressure examination as well as biochemical analyses such as: serum concentrations of glucose, insulin, adi-
ponectin, resistin, leptin, TNF-a, IL-6, hs-CRP, total cholesterol, HDL, and triglycerides.
Results: A significantly lower concentration of adiponectin, and a higher concentration of IL-6, was observed in patients with metabolic
syndrome (MS) in comparison to nonMS. Moreover, higher concentrations of hs-CRP and TNF-a were observed in patients with metabolic
syndrome.
Conclusions: A decreased concentration of adiponectin in obese people is an early predictor of metabolic syndrome. A low adiponectin
level could be a marker of high risk of cardiovascular disease in obese patients.
(Pol J Endocrinol 2010; 61 (1): 36–41)
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Streszczenie
Wstęp: Wraz z epidemią otyłości rośnie częstość powikłań będących konsekwencją nadmiaru tkanki tłuszczowej. Spowodowane nad-
wagą, niekorzystne zmiany w sekrecji adipokin przez tkankę tłuszczową, mają wpływ na rozwój powikłań metabolicznych.
Celem pracy była ocena różnic w stężeniu adipokin pomiędzy osobami otyłymi z zespołem metabolicznym, w porównaniu z obiema
osobami otyłymi bez zespołu metabolicznego.
Materiał i metody: Badaniem objęto 55 osób z nadwagą lub otyłością, u 38 badanych rozpoznano zespół metaboliczny według kryteriów
Międzynarodowej Federacji Diabetyków (IDF, International Diabetes Federation). Wykonano badania antropometryczne, pomiar ciśnienia
tętniczego oraz analizy biochemiczne, takie jak: stężenie w surowicy glukozy, insuliny, adiponektyny, rezystyny, leptyny, TNF-a, IL-6,
hs-CRP, cholesterolu całkowitego i frakcji HDL oraz triglicerydów.
Wyniki: U osób z zespołem metabolicznym, w porównaniu z osobami bez zespołu, zaobserwowano istotnie niższe stężenie adiponekty-
ny, natomiast stężenie IL-6 było istotnie wyższe. Zanotowano też wyższe stężenie hs-CRP i TNF-a u osób z zespołem metabolicznym,
różnica ta nie była jednak istotna statystycznie.
Wnioski: Niskie stężenie w surowicy adiponektyny u osób otyłych było predyktorem zespołu metabolicznego. Ponadto niskie stężenie
adiponektyny może być markerem wysokiego ryzyka chorób sercowo-naczyniowych u otyłych pacjentów.
(Endokrynol Pol 2010; 61 (1): 36–41)
Słowa kluczowe: zespół metaboliczny, otyłość, adipokiny
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Introduction
Obesity is a chronic disease that concerns over a billion
adult people all over the world. It involves several com-
plications and increases the risk of other diseases like
metabolic syndrome, diabetes mellitus type 2, or coro-
nary heart disease [1–3]. Lack of proper diet, lack of
physical activity, and socio-cultural and genetic factors
have been known as common causes of metabolic syn-
drome [4]. The newest studies concentrate mostly on
such factors as sub-clinical inflammatory process and
hormonal activity of adipose tissue [5].
Adipose tissue is a place of synthesis of several me-
tabolically active proteins called adipokines. These pro-
teins play an important role in the regulation of meta-
bolic processes, thus having auto- and paracrine func-
tion. What is more, they regulate systemic processes
showing typical endocrine activity. Thus, adipose tis-
sue is a significant element of the endocrine system in
humans [6–10].
Free fatty acids and adipokines synthesized in adi-
pose tissue have a significant influence on glucose ho-
meostasis. Adipokines are the main regulators of insu-
lin sensitivity and therefore a potential link between
obesity and insulin resistance [11, 12]. Disturbances in
the secretion of hormones and inflammatory cytokines
caused by obesity may have an influence on the deve-
lopment of typical metabolic complications [13].
Adipose tissue in its endocrine function is not a ho-
mogenous organ. There are significant differences be-
tween subcutaneous and visceral adipose tissue. Syn-
thesized hormones within visceral tissue undergo se-
cretion processes to portal circulation having a direct
influence on metabolic processes in the liver. Substan-
ces that are produced in subcutaneous adipose tissue
are secreted to systemic circulation. Secretion of such
cytokines as IL-6 and PAI-1 is much higher in visceral
adipose tissue whereas synthesis of leptin, adiponectin,
and TNF-a takes place in subcutaneous adipose tissue.
The differences also concern expression of the re-
ceptors. In other words, adipose tissue is a heterogene-
ous organ in which a secretory function depends on its
localization [7, 8, 14]. It may be the reason why central
obesity, which is typical for metabolic syndrome, has
a stronger correlation to the metabolic complications.
The aim of this study was an investigation of adipo-
kines profile in overweight or obese people with meta-
bolic syndrome, in comparison to overweight/obese
patients without metabolic syndrome.
Material and methods
The study was performed on two groups consisting of
38 obese or overweight patients (BMI > 25 kg/m2) wi-
thout metabolic syndrome (nonMS) and 17 patients
with recognized metabolic syndrome (MS), according
to International Diabetes Federation (IDF) criteria. To
be diagnosed as having metabolic syndrome, patients
had to demonstrate abdominal obesity (waist circum-
ference ≥ 94 cm in men and ≥ 80 cm in women) and
fulfil at least two out of four criteria, such as:
— triglycerides concentration ≥ 150 mg/dl or treatment
of hypertrigliceridaemia;
— concentration of cholesterol of HDL fraction < 40 mg/dl
in men and < 50 mg/dl in women or dyslipidaemia
treatment;
— systolic blood pressure (SBP) ≥ 130 mm Hg or dia-
stolic blood pressure (DBP) ≥ 85 mmHg or hyper-
tension;
— fasting glucose concentration in plasma ≥ 100 mg/dl
or diagnosed type 2 diabetes [15].
Based on interviews and examinations, patients with
secondary obesity were excluded from the study. Ho-
wever, women taking oral contraceptives, hormonal
replacement therapy, within 6 months of delivery or
breastfeeding, and patients with endocrine, mental,
malignant or serious internal diseases were excluded.
The patients were interviewed about their lifestyle
and diet, and underwent anthropometrical, biochemi-
cal measurements and blood-pressure examination.
Anthropometrical measurements
The following measurements were determined:
— body mass (kg), waist circumference (cm), hip cir-
cumference (cm);
— BMI (body mass index) — estimated according to
the current body mass/height2 [kg/m2]. BMI in the
range 25–30 kg/m2 was recorded as overweight, and
BMI ≥ 30 kg/m2 was recorded as obese [3];
— WHR (waist to hip ratio) — estimated based on wa-
ist to hip circumferences ratio;
— body composition: body fat content (%F) and lean
body mass (LBM) was obtained by near-infrared
spectroscopy method (NIR) using a Futrex 5000A
unit (Gatesburg Inc., USA).
Body mass and height were measured with attested
electronic scales with a body-height measuring device.
Laboratory assay
The samples of blood were taken after 12 hours of over-
night fasting and the levels of the following compounds
were measured in plasma:
— glucose by enzymatic-calorimetric EMAPOL me-
thod;
— insulin by MEIA method (microparticle enzyme im-
munoassay) using units and IMX by Abbott (USA);
— leptin by ELISA method, DRG Germany units and
read on a STAT FAX 2200 (USA);
— adiponectin by ELISA method, Linco (USA);
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— resistin by ELISA method, Linco (USA);
— TNF-a by ELISA method, Bender MedSystem (Au-
stria);
— hs- CRP by ELISA method, DRG (Germany);
— IL-6 by ELISA method, Bender MedSystem (Austria);
— total cholesterol (TC), triglycerides (TG), and
HDL-cholesterol (HDL) by routine methods using
a Hitachi 911.
Insulin-resistance HOMA1-IR index was calculated
according to the formula: fasting insulin (mU/L) × fa-
sting glucose level (mmol/L): 22.5 [16]. Blood pressure
was checked twice, sitting and after at least 15 minutes
of relaxation, using a proper sleeve. In this study, an
average from the two measurements is given.
Statistical analysis
Statistical analysis was performed using Statistica 7.1
version for Windows (Krakow, Poland). All data were
expressed as mean ± standard deviation (SD). Compa-
risons of the groups were examined by Student’s t-test.
Pearson correlation test was used to determine the re-
lationship between continuous variables. The indepen-
dent determinations of metabolic syndrome were made
using logistic regression analysis. P value < 0.05 was
considered statistically significant for all analyses.
Results
The studied population consisted of 55 patients
(38 women, 17 men) with a mean age of 38.8 ± 10.2 years
(range 19–59) and was divided into two groups:
— the MS group consisted of 38 overweight patients
(69%, 24 women, 12 men) with metabolic syndrome
— the non MS group consisted of 17 overweight pa-
tients (31%, 11 women, 5 men) without diagnosed
metabolic syndrome.
There were 21% overweight, 58% obese (I° or II°),
and 21% with extreme obesity in the MS group. Meta-
bolic syndrome was manifested in all patients with
extreme obesity (Fig. 1).
The criteria of metabolic syndrome were presented
in the following levels:
— lowered concentration of HDL cholesterol 87.0%,
— hypertension 76.3%,
— hypertrigliceridaemia 76.3%,
— hyperglycaemia 26.3%.
As expected, HDL cholesterol and triglyceride con-
centrations, as well as values of systolic and diastolic
blood pressure, were significantly different between the
MS and non MS groups. However, no statistically si-
gnificant differences were observed in concentrations
of total cholesterol and LDL cholesterol.
In the MS group, the mean BMI (35.6 kg/m2) and
%F (43.1%) were statistically higher when compared to
nonMS group (BMI — 29.8 kg/m2; %F — 37.9%)
(Table I).
In the MS and non MS groups, the mean insulin con-
centration was 26.4 mIU/ml and 14.7 mIU/ml, with mean
HOMA index values of 6.1 and 3.1, respectively. The dif-
ferences in these parameters of insulin resistance betwe-
en the groups were statistically significant (Table II).
The MS v. non MS patients exhibited significantly
lower levels of adiponectin (15 mg/ml v. 20.6 mg/ml), and
significantly higher concentrations of IL-6 (3.2 pg/ml v.
2.5 pg/ml) and hs-CRP (8.41 mg/L v. 6.5 mg/L). Whereas
Table I. Anthropometrical parameters and level of blood
pressure in the MS and non MS groups
Tabela I. Parametry antropometryczne i wartości ciśnienia
tętniczego w grupach MS i non MS
Parameters MS non MS p
(n = 38) (n = 17)
BMI [kg/m2] < 0.001
mean ± SD 35.6 ± 6.1 29.8 ± 3.7
range 27.2–51.0 26.0–38.3
F (%) 0.006
mean ± SD 43.1 ± 7.5 37.9 ± 5.7
range 27.9–60.0 25.0–49.3
F [kg] < 0.001
mean ± SD 44.8 ± 14.4 31.8 ± 8.3
range 25.4–81.0 21.3–50.8
SBP [mm Hg] < 0.001
mean ± SD 134.7 ± 17.3 104.1 ± 8.3
range 100–170 100–132
DBP [mm Hg] < 0.001
mean ± SD 85.5 ± 10.7 71.2 ± 6.0
range 60–100 60–85
Figure 1. The frequency of metabolic syndrome depend on to BMI
Rycina 1. Częstość występowania zespołu metabolicznego
w zależności od BMI
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Table II. Insulin concentration and HOMA index in the MS
and non MS  groups
Tabela II. Stężenia insuliny i wskaźniki HOMA w grupach
MS i non MS
Parameters MS non MS p
(n = 38) (n = 17)
Insulin [mIU/ml] 0.005
mean ± SD 26.4 ± 18.7 14.7 ± 9.1
range 8.3–89.0 5.5–35.8
HOMA 0.002
mean ± SD 6.1 ± 4.4 3.1 ± 1.9
range 1.8–21.4 1.1–7.8
Table III. Biochemical parameters in the MS and non MS
groups
Tabela III. Parametry biochemiczne w grupach MS i non MS
Parameters MS non MS p
(n = 38) (n = 17)
hs-CRP [mg/L] ns  (0.190)
mean ± SD 8.4 ± 3.8 6.6 ± 4.1
range 1.0–10.6 1.1–10.6
Total cholesterol ns
[mg/dl]
mean ± SD 227 ± 55 206 ± 33
range 152–452 161–283
LDL cholesterol ns
[mg/dl]
mean ± SD 144 ± 49 130 ± 29
range 66–359 95–190
HDL cholesterol < 0.001
[mg/dl]
mean ± SD 40.3 ± 8.1 56.4 ± 8.6
range 27.4–62.0 34.9–70.0
Triglycerides < 0.001
[mg/dl]
mean ± SD 203 ± 94 97 ± 44
range 37–457 52–231
Adiponectin [mg/ml] 0.038
mean ± SD 15.0 ± 7.2 20.6 ± 12.0
range 3.1–39.0 6.4–46.7
Resistin [ng/ml]
mean ± SD 25.1 ± 17.3 25.0 ± 13.9 ns
range 2.2–70.5 8.7–55.7
Leptin [ng/ml]
mean ± SD 7.9 ± 10.5 8.3 ± 12.5 ns
range 0.5–39.5 0.5–40.5
TNF-a [pg/ml]
mean ± SD 18.4 ± 13.4 12.8 ± 4.6 ns
range 5–66 6–22
IL-6 [pg/ml]
mean ± SD 3.2 ± 0.9 2.5 ± 0.4 0.012
range 2–6 1.8–3.2
Table IV. Results of logistic regression (p < 0.001). The
dependence variable: occurrence of metabolic syndrome acc
IDF criteria
Tabela IV. Wyniki regresji logistycznej (p < 0,001). Zmienna
zależna: występowanie zespołu metabolicznego zdefiniowanego
według kryteriów IDF
Independent variable p
BMI [kg/m2] 0.006
Adiponectin [mg/ml] 0.017
HOMA* 0.034
Insulin [mIU/ml]* 0.039
* — logarithm
the values observed for other analyzed adipokines did
not differ between these groups (Table III).
The analysis of logistical regression showed that in-
creased BMI, as well as decreased adiponectin concen-
tration, were the biggest factors stimulating manifesta-
tion of metabolic syndrome (Table IV). In univariate
analysis, the negative correlations between adiponec-
tin and WHR , insulin and HOMA-IR index value were
observed for all studied patients.
In addition, adiponectin correlated positively with
HDL cholesterol and negatively with triglyceride levels
(Table V) in the whole studied population. Moreover,
a negative correlation was observed between adiponec-
tin and SBP as well as DBP (p < 0.001 for both varia-
bles) (Table VI).
Discussion
The MS group, in comparison to patients without meta-
bolic syndrome, had higher values of BMI and %F as well,
and as expected, higher values of SBP and DBP. Similar
results were also observed in other studies [17, 18].
In our studies, patients with recognized metabolic
syndrome had almost two times higher values of insulin
concentration and HOMA index. In addition, this obse-
rvation has been confirmed by other authors [18, 19].
The results of our study have shown that patients who
fulfilled metabolic syndrome criteria had significantly
lower adiponectin levels by about 25% in the MS group.
Other authors also described lower adiponectin concen-
trations in patients with metabolic syndrome (according
to both criteria — ATP III and IDF) [20–24].
Body mass index and adiponectin concentration, ac-
cording to the results of the logistical regression, had
a decisive influence on the development of metabolic
syndrome. Similarly, Shaibi and others [20] suggested
that hypoadiponectinaemia is an independent predic-
tor of metabolic syndrome.
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Adiponectin has a stronger correlation to the possi-
bility of metabolic syndrome occurrence than such in-
flammatory state parameters as hs-CRP and IL-6 [21].
Hence adiponectin may become a routine laboratory
measurement for estimating the risk factor for the oc-
currence of metabolic syndrome [25, 26].
The concentrations of pro-inflammatory adipokines
and cytokines such as resistin, leptin, and TNF-a were
similar in MS and nonMS group. IL-6 was the only one
that was higher in the group with metabolic syndrome.
Other authors [18, 23] have also failed to show any diffe-
rences in leptin and resistin concentrations between pa-
tients with and without metabolic syndrome.
The results concerning levels of TNF-a are divergent.
Similarly to our study, You and others did not observe any
difference in TNF-a between patients with and without
metabolic syndrome [19]. Others described higher concen-
trations of this cytokine in patients with metabolic syndro-
Table V. Results of univariate correlation between the studied parameters
Tabela V. Wyniki korelacji jednozmiennowej pomiędzy badanymi parametrami
Total Cholesterol LDL Cholesterol HDL Cholesterol Triglycerides TNF-a IL- 6 hs-CRP
Adiponectin –0.07 –0.01 –0.43*** –0.27* –0.26* –0.14 –0.18
Resistin –0.10 –0.03 –0.14 –0.27* –0.10 –0.0 –0.2
Leptin –0.12 –0.09 –0.02 –0.10 –0.09 –0.01 –0.16
TNF-a –0.1 –0.1 –0.2 –0.06 – –0.2 –0.19
IL-6 –0.16 –0.02 –0.24 –0.04 – – –0.14
hs-CRP –0.05 –0.21 –0.15 –0.1 – – –
*p £ 0.05, **p £ 0.01, ***p £ 0.001
Table VI. Results of univariate correlation between the studied parameters
Tabela VI. Wyniki korelacji jednozmiennowej pomiędzy badanymi parametrami
Insulin HOMA WHR Waist F F BMI
[mIU/ml] circumference (%) [kg] [kg/m2]
[cm]
Adiponectin –0.45*** –0.44*** –0.4** –0.18 0.32 0.06 –0.03
Resistin –0.10 –0.09 –0.25 0.07 0.15 0.22 0.17
Leptin –0.09 –0.09 –0.2 0.06 0.08 0.17 0.2
TNF-a 0.19 0.2 0.10 0.02 –0.21 –0.10 –0.06
IL-6 0.14 0.15 0.13 0.34** 0.28* 0.29* 0.3*
hs-CRP 0.47*** 0.43*** –0.08 0.26 0.34* 0.44*** 0.51***
Total Cholesterol –0.04 –0.02 0.07 0.00 0.17 0.08 0.04
LDL Cholesterol 0.1 0.08 0.07 0.08 0.3* 0.18 0.13
HDL Cholesterol –0.39** –0.39** –0.26 –0.23 0.01 –0.18 –0.27*
Triglycerides 0.08 0.10 0.24 0.14 0.08 0.12 0.13
Insulin [mIU/ml] – – 0.13 0.38** 0.22 0.46*** 0.5***
HOMA – – 0.10 0.4 ** 0.21 0.48*** 0.52***
*p £ 0.05, **p £ 0.01, ***p £ 0.001
me but only when ATP III criteria are taken into consi-
deration (not according to IDF) [18, 21, 27].
In our study, hs-CRP did not differ but only sho-
wed a tendency towards higher concentration in the
group with metabolic syndrome. It is in agreement with
observations made by other authors who did not de-
scribe any difference in hs-CRP concentrations betwe-
en obese people with and without metabolic syndrome
[18, 19]. Nevertheless, higher concentrations of hs-CRP
were even described in teenagers with metabolic syn-
drome. Hs-CRP value > 3 mg/L was noted 3.5 times
more often in patients with metabolic syndrome than
in those without [28]. It is worth mentioning that in
multivariate regression analysis, waist circumference
was the only component of metabolic syndrome that
had a significant influence on hs-CRP.
Komatsu and others [24] suggest that the increase
of hs-CRP concentration is a later phenomenon than
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the decrease in adiponectin concentration; thus, hs-CRP
concentration may be normal at the beginning of meta-
bolic syndrome occurrence. This may explain the re-
sults observed by us.
In our study, plasma concentrations of adiponectin
were significantly higher in the MS group (Table III), in
comparison to the nonMS group. However, adiponec-
tin levels became lower along with an increase in insu-
lin resistance and obesity. Some authors have confir-
med such a correlation [29–35]. Altinova and others [36]
suggested, on the basis of multivariate analysis, that
adiponectin concentration has a decisive influence on
insulin resistance level.
In the studied group, decreased concentrations of
adiponectin co-existed with low HDL cholesterol and
increased triglycerides. No correlation has been found
between adiponectin and total cholesterol and LDL frac-
tion. In addition, we observed a negative correlation
between adiponectin and SBP and DBP. Thus, along
with the decrease in adiponectin concentration, lipid
disturbances and hypertension are observed — typical
for metabolic syndrome. These results suggest a rela-
tion between hypoadiponectinaemia and increased
metabolic complications [33, 37, 38].
Summary
Incidence rates of metabolic syndrome increase with
obesity intensification; however, it is not present in all
obese persons. Apart from obesity rate, genetic predi-
spositions also have an influence on metabolic syndro-
me manifestation. It seems to be useful to isolate sub-
jects with high risk of complications in the population
of obese patients. One such a marker can be adiponec-
tin, the level of which correlates with the presence of
cardiovascular complications. Identification of low adi-
ponectin level obese patients could offer them particu-
lar care due to enhanced mortality risk.
Conclusions
1. In obese people, a low concentration of adiponectin
correlates with disturbances typical for metabolic
syndrome. Therefore, hypoadiponectinaemia can be
a factor influencing the development of the meta-
bolic disorders.
2. Adiponectin concentration could be a marker of high
risk of cardiovascular diseases in obese patients with,
and without, metabolic syndrome.
References
1. Pudel V, Ellrott T. Adipositas — ein gesellschaftspolitisches Problem?
Chirurg 2005; 76: 639–646.
2. Reincke M. Adipositas und Innere Medizin. Internist 2006; 47: 109.
3. World Health Organization. Obesity: Preventing and Managing the Global
Epidemic. Report of a World Health Organization Consultation. Geneva,
Switzerland: World Health Organization, 2000. WHO Obesity Technical
Report Series, No. 894.
4. Groop L, Orho-Melander M. The dysmetabolic syndrome. J Intern Med
2001; 250: 105–120.
5. Hanefeld M, Schaper F, Ceriello A. Geschichte und Definition(en) des
metabolischen Syndroms. Internist 2007; 48: 107–125.
6. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endo-
criol Metab 2000; 10: 327–332.
7. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endo-
crinol Metab 2004; 89: 2548–2556.
8. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocri-
ne and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1045–1058.
9. Fischer-Posovszky P, Wabitsch M. Entwicklung und Funktion des Fett-
gewebes. Monatsschr Kinderheilkd 2004; 152: 834–842.
10. Trayhurn P. Adipocyte biology. Obes Rev 2007; 8 (Suppl.1): 41–44.
11. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resi-
stance. Diabetologia 2003; 46: 1594–1603.
12. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and Insulin Resi-
stance. J Clin Endocrinol Metab 2004; 89: 447–452.
13. Ronti T, Lupattelli G, Monnarino E. The endocrine function of adipose
tissue: an update. Clin Endocrinol 2006; 64: 355–365.
14. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr
Soc 2001; 60: 349–356.
15. International Diabetes Federation. The IDF consensus worldwide defini-
tion of the metabolic syndrome 2005. www.idf.org
16. Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Mode-
ling. Diabetes Care 2004; 27: 1487–1495.
17. Anand SS, Yi Q, Gerstein H et al. Relationship of Metabolic Syndrome
and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation 2003;
108: 420–425.
18. Xydakis AM, Case CC, Jones PH et al. Adiponectin, Inflammation, and
the Expression of the Metabolic Syndrome in Obese Individuals: The
Impact of Rapid Weight Loss through Caloric Restriction. J Clin Endocri-
nol Metab 2004; 89: 2697–2703.
19. You T, Ryan AS, Niclas B. The Metabolic Syndrome in Obese Postmeno-
pausal Women: Relationship to Body Composition, Visceral Fat, and In-
flammation. J Clin Endocrinol Metab 2004; 89: 5517–5522.
20. Shaibi GQ, Cruz ML, Weigensberg MJ et al. Adiponectin Independently
Predict Metabolic Syndrome in Overweight Latino Youth. J Clin Endo-
crinol Metab 2007; 92: 1809–1813.
21. Matsushita K, Yatsuya H, Tamakoshi K et al. Comparison of Circulating
Adiponectin and Proinflammatory Markers Regarding Their Association
With Metabolic Syndrome in Japanese Men. Arterioscler Thromb Vasc
Biol 2006; 26: 871–876.
22. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a Biomarker of the
Metabolic Syndrome. Circ J 2004; 68: 975–981.
23. Bahia L, Aguiar LG, Villela N et al. Relationship between adipokines,
inflammation, and vascular reactivity in lean controls and obese subjects
with metabolic syndrome. Clinics 2006; 61: 433–440.
24. Komatsu M, Ohfusa H, Aizawa T et al. Adiponectin Inversely Correlates
with High Sensitive C-reactive Protein and Triglycerides, but not with
Insulin Sensitivity, in Apparently Healthy Japanese Men. Endocr J 2007;
54: 553–558.
25. Sharma AM, Tarnopolsky MA. Regulating adiponectin: of flax and flux.
Diabetologia 2005; 48: 1035–1037.
26. Trujillo ME, Scherer PE. Adiponectin — journey from an adipocyte se-
cretory protein to biomarker of the metabolic syndrome. J Int Med 2005;
257: 167–175.
27. Rogulski L, Lisikiewicz B, Nowak R. Stężenie TNF-a w osoczu otyłych
pacjentów z zespołem metabolicznym. Diabetologia Doświadczalna
i Kliniczna 2005; 5: 381–385.
28. Ridker PM, Buring JE, Cook NR et al. C-Reactive Protein, the Metabolic
Syndrome, and Risk of Incident Cardiovascular Events. Circulation 2003;
107: 391–397.
29. Festa A, D’Agostino R, Howard G et al. Chronic Subclinical Inflamma-
tion as Part of the Insulin Resistance Syndrome. Circulation 2000; 102:
42–47.
30. Frölich M, Imhof A, Berg G . Association Between C-Reactive Protein and
Features of the Metabolic Syndrome. Diabetes Care 2000; 23: 1835–1839.
31. Ford ES, Ajani UA, Mokdad AH. The Metabolic Syndrome and Concen-
trations of C-Reactive Protein Among U.S. Youth. Diabetes Care 2005; 28:
878–881.
32. Shand BI, Scott RS, Elder PA et al. Plasma adiponectin in overweight,
nondiabetic individuals with or without insulin resistnce. Diabetes Obes
Metab 2003; 5: 349–353.
33. Baratta R, Amato S, Degano C et al. Adiponectin Relationship with Lipid
Metabolism is Independent of Body Fat Mass: Evidence from Both Cross-
-Sectional and Interventional Studies. J Clin Endocrinol Metab 2004; 89:
2665–2671.
34. Bruun JM, Lihn AS, Verdich C et al. Regulation of adiponectin by adipo-
se tissue-derived cytokines: in vivo and in vitro investigations in humans.
Am J Physiol Endocrinol Metab 2003; 285: E527–E533.
35. Cnop M, Havel PJ, Utzschneider KM et al. Relationship of adiponectin to
body fat distribution, insulin sensitivity and plasma lipoproteines: eviden-
ce for independent roles of age and sex. Diabetologia 2003; 46: 459–469.
36. Altinova AE, Toruner F, Bukan N et al. Decreased Plasma Adiponectin is
Associated with Insulin Resistance and HDL Cholesterol in Overweight
Subjects. Endocr J 2007; 54: 221–226.
37. Shaibi GQ, Cruz ML, Weigensberg MJ et al. Adiponectin Independently
Predict Metabolic Syndrome in Overweight Latino Youth. J Clin Endo-
crinol Metab 2007; 92: 1809–1813.
38. Ryo M, Nakamura T, Kihara S et al. Adiponectin as a Biomarker of the
Metabolic Syndrome. Circ J 2004; 68: 975–981.
